CN1034415C - 新抗坏血酸衍生物的制备方法 - Google Patents

新抗坏血酸衍生物的制备方法 Download PDF

Info

Publication number
CN1034415C
CN1034415C CN91101600A CN91101600A CN1034415C CN 1034415 C CN1034415 C CN 1034415C CN 91101600 A CN91101600 A CN 91101600A CN 91101600 A CN91101600 A CN 91101600A CN 1034415 C CN1034415 C CN 1034415C
Authority
CN
China
Prior art keywords
compound
acid
alkyl
salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN91101600A
Other languages
English (en)
Chinese (zh)
Other versions
CN1054978A (zh
Inventor
马斯倪克·吉尔伯特
格里萨·J·马酊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Merrell Dow Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Ltd filed Critical Merrell Dow Pharmaceuticals Ltd
Publication of CN1054978A publication Critical patent/CN1054978A/zh
Application granted granted Critical
Publication of CN1034415C publication Critical patent/CN1034415C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
CN91101600A 1990-03-16 1991-03-16 新抗坏血酸衍生物的制备方法 Expired - Fee Related CN1034415C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90400731A EP0446539A1 (en) 1990-03-16 1990-03-16 Novel ascorbic acid derivatives
EP90400731.7 1990-03-16

Publications (2)

Publication Number Publication Date
CN1054978A CN1054978A (zh) 1991-10-02
CN1034415C true CN1034415C (zh) 1997-04-02

Family

ID=8205691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN91101600A Expired - Fee Related CN1034415C (zh) 1990-03-16 1991-03-16 新抗坏血酸衍生物的制备方法

Country Status (21)

Country Link
US (1) US5175188A (enExample)
EP (2) EP0446539A1 (enExample)
JP (1) JP3029055B2 (enExample)
KR (1) KR0171190B1 (enExample)
CN (1) CN1034415C (enExample)
AT (1) ATE137230T1 (enExample)
AU (1) AU632907B2 (enExample)
CA (1) CA2038416C (enExample)
DE (1) DE69118955T2 (enExample)
DK (1) DK0447325T5 (enExample)
ES (1) ES2089159T3 (enExample)
FI (1) FI97884C (enExample)
GR (1) GR3020411T3 (enExample)
HU (1) HU208004B (enExample)
IE (1) IE910879A1 (enExample)
IL (1) IL97574A (enExample)
NO (1) NO177705C (enExample)
NZ (1) NZ237400A (enExample)
PT (1) PT97041B (enExample)
TW (1) TW213455B (enExample)
ZA (1) ZA911994B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU214331B (hu) * 1992-06-17 1998-03-02 Gyógyszerkutató Intézet Kft. Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
HRP930131A2 (en) * 1993-02-05 1997-02-28 Bozidar Suskovic Amino-ascorbic acid derivatives, process for the preparation and use thereof
US5559251A (en) * 1993-02-05 1996-09-24 Pliva, Farmaceutska Derivatives of amino-ascorbic acid, the processes for their preparation and use
RU2126398C1 (ru) * 1993-02-05 1999-02-20 Плива, Фармацеутска, Кемийска, Прехрамбена и Козметичка Индустрия Дионичко Друштво Загреб Производные аминоаскорбиновой кислоты, способы их получения и производные галоидаскорбиновой кислоты
FR2946252B1 (fr) * 2009-06-08 2011-07-29 Fabre Pierre Dermo Cosmetique Bis esters d'acide gras insature sur l'acide ascorbique et leurs utilisations cosmetiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368330A (en) * 1981-04-30 1983-01-11 Pfizer Inc. Derivatives of L-ascorbic acid and D-erythorbic acid
GB2114571A (en) * 1982-01-15 1983-08-24 Lilly Co Eli Ascorbic acid ethers and related compounds
EP0202589A2 (en) * 1985-05-17 1986-11-26 Takeda Chemical Industries, Ltd. Pharmaceutical compositions containing ascorbic acid derivatives
EP0259707A2 (en) * 1986-08-29 1988-03-16 Takeda Chemical Industries, Ltd. Hydroxybutenolide derivatives, production and use thereof
EP0277900A2 (en) * 1987-01-07 1988-08-10 Centro Marga Para La Investigacion S.A. H2-Receptor antagonist compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368330A (en) * 1981-04-30 1983-01-11 Pfizer Inc. Derivatives of L-ascorbic acid and D-erythorbic acid
GB2114571A (en) * 1982-01-15 1983-08-24 Lilly Co Eli Ascorbic acid ethers and related compounds
EP0202589A2 (en) * 1985-05-17 1986-11-26 Takeda Chemical Industries, Ltd. Pharmaceutical compositions containing ascorbic acid derivatives
EP0259707A2 (en) * 1986-08-29 1988-03-16 Takeda Chemical Industries, Ltd. Hydroxybutenolide derivatives, production and use thereof
EP0277900A2 (en) * 1987-01-07 1988-08-10 Centro Marga Para La Investigacion S.A. H2-Receptor antagonist compounds

Also Published As

Publication number Publication date
ES2089159T3 (es) 1996-10-01
FI911282L (fi) 1991-09-17
CA2038416C (en) 2003-03-11
NO911051D0 (no) 1991-03-15
EP0446539A1 (en) 1991-09-18
EP0447325A1 (en) 1991-09-18
KR0171190B1 (ko) 1999-02-01
NO177705B (no) 1995-07-31
KR910016732A (ko) 1991-11-05
FI911282A0 (fi) 1991-03-15
AU632907B2 (en) 1993-01-14
DE69118955T2 (de) 1996-09-19
TW213455B (enExample) 1993-09-21
NO911051L (no) 1991-09-17
FI97884C (fi) 1997-03-10
FI97884B (fi) 1996-11-29
JPH04234869A (ja) 1992-08-24
US5175188A (en) 1992-12-29
AU7287891A (en) 1991-10-10
HU208004B (en) 1993-07-28
EP0447325B1 (en) 1996-04-24
HUT56559A (en) 1991-09-30
PT97041A (pt) 1991-10-31
IL97574A (en) 1995-10-31
JP3029055B2 (ja) 2000-04-04
ATE137230T1 (de) 1996-05-15
NZ237400A (en) 1993-05-26
PT97041B (pt) 1998-07-31
IL97574A0 (en) 1992-06-21
CA2038416A1 (en) 1991-09-17
CN1054978A (zh) 1991-10-02
DE69118955D1 (de) 1996-05-30
IE910879A1 (en) 1991-09-25
DK0447325T5 (da) 1996-05-28
GR3020411T3 (en) 1996-09-30
ZA911994B (en) 1991-12-24
NO177705C (no) 1995-11-08

Similar Documents

Publication Publication Date Title
JPH0456840B2 (enExample)
JPH0729922B2 (ja) ２‐アルコキシ‐ｎ‐（１‐アザビシクロ［２，２，２オクト‐３‐イル）ベンズアミド類およびチオベンズアミド類
CN87103096A (zh) N-(2′-氨基苯基)-苯甲酰胺衍生物其制备方法以及含它们的药物组合物
JPH0725785B2 (ja) アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
CN1041760A (zh) 咪唑啉衍生物及其制备方法
CN1033972C (zh) 制备2h-1-苯并吡喃化合物的方法
CN1034415C (zh) 新抗坏血酸衍生物的制备方法
JPS6229566A (ja) 新規グアニジノメチル安息香酸誘導体
JPH0625091B2 (ja) ジヒドロジベンゾシクロヘプチリデン―エチルアミン誘導体その製法ならびに医薬組成物
US3843796A (en) Antihypertensive agents
CA2511325A1 (en) Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
EP0350878A2 (en) Conjugated gamma-oxybutenolide compounds for treating ulcer
US3836656A (en) Substituted purines as hypolipidemics
CA1044235A (en) Cyclopentene and cyclopentane derivatives
US3767674A (en) Cyclohexeno thioxanthones
US4515806A (en) Furan derivatives and addition salts thereof pharmaceutical compositions and the therapeutical applications thereof
CN1224626C (zh) β－D－5－硫代木糖衍生物、其制备方法及医疗用途
US4034011A (en) 1,1-Diphenyl-4-(substituted-amino)butanes
JPH02115160A (ja) チオホルムアミジン
CN111556746A (zh) 青蒿酸糖缀合物化合物、其制备和使用方法
CN1309125A (zh) 具抗癌活性的藤黄酸类化合物的复合物及其制备方法
TW445261B (en) A substituted thiophenylalkenylcarboxylic acid guanidide compound having the cellular Na<SP>+</SP>/H<SP>+</SP> exchanger inhibitory activity, the preparation processes and the pharmaceutical compositions thereof
US4857529A (en) Interferon inducing, anti-vaccinia, and/or anti-influenza compositions
BG108065A (bg) Нова бензоилгуанидинова сол
CN1033809A (zh) 6-氯-4-羟基-2-甲基-N-(2-吡啶基)-2H-噻吩并(2，3-e)-1，2-噻嗪-3-羧基酰胺1，1-二氧化物烯醇醚类化合物，其制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
MM4A Cease of patent right caused by unpayment of annual fee